Releasing the brake on the immune system: The PD-1 strategy for hematologic malignancies

Locke J. Bryan; Leo I. Gordon

Releasing the brake on the immune system: The PD-1 strategy for hematologic malignancies

Research output: Contribution to journal › Article › peer-review

Abstract

Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.

Original language	English (US)
Journal	ONCOLOGY (United States)
Volume	29
Issue number	6
State	Published - Jun 15 2015
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{9bf3b52bf9344f09a5b6298ec1032dc3,

title = "Releasing the brake on the immune system: The PD-1 strategy for hematologic malignancies",

abstract = "Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.",

author = "Bryan, {Locke J.} and Gordon, {Leo I.}",

year = "2015",

month = jun,

day = "15",

language = "English (US)",

volume = "29",

journal = "ONCOLOGY (United States)",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "6",

}

TY - JOUR

T1 - Releasing the brake on the immune system

T2 - The PD-1 strategy for hematologic malignancies

AU - Bryan, Locke J.

AU - Gordon, Leo I.

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.

AB - Incorporation of PD-1 blockade into the treatment algorithms for hematologic malignancies is currently being pursued in multiple active clinical trials. Here we review the data on anti–PD-1 monoclonal antibodies to date and discuss ongoing and future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84935022408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935022408&partnerID=8YFLogxK

M3 - Article

C2 - 26091677

AN - SCOPUS:84935022408

SN - 0890-9091

VL - 29

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

IS - 6

ER -

Releasing the brake on the immune system: The PD-1 strategy for hematologic malignancies

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this